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Administration of cathelicidin exerts effective antiﬁbrogenic
effects in colitis associated intestinal ﬁbrosis. Cathelicidin
inhibits transforming growth factor b1-induced collagen
expression in ﬁbroblasts. The antiﬁbrogenic effect is
extracellular-regulated kinase pathway dependent.
BACKGROUND & AIMS: Cathelicidin (LL-37 in human and
mCRAMP in mice) represents a family of endogenous antimi-
crobial peptides with anti-inﬂammatory effects. LL-37 also
suppresses collagen synthesis, an important ﬁbrotic response,
in dermal ﬁbroblasts. Here, we determined whether exogenous
cathelicidin administration modulates intestinal ﬁbrosis in two
animal models of intestinal inﬂammation and in human colonic
ﬁbroblasts.
METHODS: C57BL/6J mice (n ¼ 6 per group) were adminis-
tered intracolonically with a trinitrobenzene sulphonic acid
(TNBS) enema to induce chronic (6–7 weeks) colitis with
ﬁbrosis. We administered mCRAMP peptide (5 mg/kg every 3
day, week 5–7) or cathelicidin gene (Camp)-expressing lenti-
virus (107 infectious units week 4) intracolonically or intrave-
nously, respectively. We then infected 129Sv/J mice with
Salmonella typhimurium orally to induce cecal inﬂammation
with ﬁbrosis. Camp-expressing lentivirus (107 infectious units
day 11) was administered intravenously.
RESULTS: TNBS-induced chronic colitis was associated with
increased colonic collagen (col1a2) mRNA expression. Intra-
colonic cathelicidin (mCRAMP peptide) administration or
intravenous delivery of lentivirus-overexpressing cathelicidin
gene signiﬁcantly reduced colonic col1a2 mRNA expression in
TNBS-exposed mice compared with vehicle administration.
Salmonella infection also caused increased cecal inﬂammation
associated with collagen (col1a2) mRNA expression that was
prevented by intravenous delivery of Camp-expressing lenti-
virus. Exposure of human primary intestinal ﬁbroblasts and
human colonic CCD-18Co ﬁbroblasts to transforming growth
factor-b1 (TGF-b1) and/or insulin-like growth factor 1
induced collagen protein and mRNA expression, which wasreduced by LL-37 (3–5 mM) through a MAP kinase-dependent
mechanism.
CONCLUSIONS: Cathelicidin can reverse intestinal ﬁbrosis by
directly inhibiting collagen synthesis in colonic ﬁbroblasts. (Cell
Mol Gastroenterol Hepatol 2015;1:55–74; http://dx.doi.org/
10.1016/j.jcmgh.2014.08.001)
Keywords: Antimicrobial Peptide; Collagen; Inﬂammatory
Bowel Disease.
nﬂammatory bowel disease (IBD), including Crohn’sIdisease (CD) and ulcerative colitis, is manifested by
chronic inﬂammation of the gastrointestinal tract with sig-
niﬁcant morbidity and at times life-threatening complica-
tions.1 Patients with chronic CD often develop transmural
luminal narrowing and form strictures caused by excessive
extracellular matrix deposition.2,3 The mechanisms of in-
testinal ﬁbrosis are complex and not well understood.
Transforming growth factor-b1 (TGF-b1) levels are often
higher in the mucosa overlying CD strictures compared with
nonstrictured gut.2 Therapies for ﬁbrosis are ineffective, and
surgical resection is often required.2 Approximately 75% of
CD patients eventually undergo surgery, most frequently
56 Yoo et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 1because of intestinal ﬁbrosis.3 Therapy with anti–tumor
necrosis factor a (anti-TNFa) monoclonal antibodies can
effectively reduce inﬂammation but may not prevent or
reverse ﬁbrosis in CD patients.4 Previous studies also haveshown that inhibition of TGF-b1 reduces colonic ﬁbrosis in a
mouse chronic colitis model.5
Cathelicidins (LL-37 in humans and mCRAMP in mice)
represent a family of endogenous antimicrobial peptides
Figure 2. Cathelicidin administration does not affect
macrophage inﬁltration in colonic tissues: immunohisto-
chemistry of macrophage marker F4/80 in colonic tis-
sues. Macrophages are identiﬁed by brown staining (arrows).
TNBS-treated mice had increased F4/80 immunostaining
compared with the ethanol control group. Intracolonic
mCRAMP treatment did not affect F4/80-expressing macro-
phage inﬁltration in TNBS-treated mice.
Figure 1. (See previous page). Cathelicidin peptide adminis
chronic colitis in mice. (A) Illustration of experimental plan
increasing doses of TNBS solution intracolonically once a wee
mCRAMP peptide or vehicle solution 0.1% of triﬂuroacetic acid (
were evaluated 2 weeks after the last TNBS injection. (B) Percent
week 7). All ethanol-treated groups had approximately 20% bo
signiﬁcantly less bodyweight gain comparedwith ethanol control
wild-typepartially restored thebodyweight gain (P¼ .0178). (C) Re
immune cell inﬁltration. Small arrows show collagen deposition a
HistologyscorewasbasedonH&Estaining imagesof colonic tissu
a statistically signiﬁcantly higher histology score (P ¼ .001) com
tistically signiﬁcantly reduced the histology score (P ¼ .03). (E) T
ﬂammatory cytokine TnfamRNA (P ¼ .0344) expression. Intracol
TNBS-induced mRNA (P ¼ .046) expression in mice. (F) Colonic
Colonic Tgf-b1 mRNA expression was not affected by intracolon
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the host from infection.5 Several studies support the impor-
tance of cathelicidins in the pathogenesis of various disease
states. Cathelicidin-deﬁcient (Camp/) mice are more sus-
ceptible to infections6 and have reduced angiogenesis and
wound healing.7,8 Park et al9 also showed that LL-37 reduces
collagen synthesis in dermal ﬁbroblasts, suggesting a po-
tential role for cathelicidins in reducing ﬁbrosis. Intracolonic
administration of mCRAMP reduces the severity of dextran
sulfate (DSS)-mediated acute colitis in mice,10 and Camp/
mice have exacerbated acute DSS-induced colitis.11 In addi-
tion, cathelicidin effectively reduces Clostridium difﬁci-
le–mediated colitis and acute C difﬁcile toxin A–induced
enteritis in mice.12 Despite its potent anti-inﬂammatory ef-
fects in acute colitis, the potential role of cathelicidin in the
development and progress of chronic colitis has not been
explored, and the possibility that cathelicidins modulate in-
testinal ﬁbrosis has never been studied.
Here we used the well-established chronic trini-
trobenzene sulphonic acid (TNBS)-induced colitis mouse
model as well as the Salmonella-mediated cecal inﬂamma-
tion model to study intestinal ﬁbrosis associated with these
models.13,14 We found that intracolonic peptide or intrave-
nous lentiviral (LV) administration of cathelicidin attenuates
colitis-associated intestinal ﬁbrosis and inﬂammation
in vivo. LL-37 reduces collagen expression induced by TGF-
b1 and insulin-like growth factor 1 (IGF-1) in human colonic
ﬁbroblasts in vitro. Our results also indicate that reduced
collagen expression in response to cathelicidin is mediated
via extracellular signal-regulated kinase (ERK) activation in
these cells.Materials and Methods
Cell Cultures
Human CCD-18Co colonic ﬁbroblasts (2  106 cells/
plate) were cultured in minimal essential medium Eagle’s
medium (American Type Culture Collection, Manassas, VA)
containing 10% fetal bovine serum (Invitrogen/Life Tech-
nologies, Carlsbad, CA) and 1% penicillin/streptomycin
(Invitrogen).15 Human primary normal intestinal ﬁbroblasts
(three normal and two CD patients) were isolated astration reduces colonic inﬂammation in TNBS-mediated
of TNBS-mediated chronic colitis. Mice were injected with
k for 6 weeks. Some mice received intracolonic injection of
control) starting from the ﬁfth TNBS injection. Colonic changes
age of body weight change of different groups (from week 0 to
dy weight gain. TNBS-treated wild-type mice had statistically
(P¼ .045). Administration ofmCRAMPpeptide to TNBS-treated
presentativeH&E imagesof colonic tissues. Large arrowsshow
nd mucosal transformation with altered cryptal architecture. (D)
es. TNBS treatment inmice led to increased tissuedamagewith
pared with the ethanol control. Treatment with mCRAMP sta-
NBS treatment statistically signiﬁcantly induced colonic proin-
onic mCRAMP administration statistically signiﬁcantly reduced
Tgf-b1 mRNA expression in mice with chronic TNBS colitis.
ic mCRAMP peptide administration. Per group, n ¼ 6 mice.
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Figure 3. Cathelicidin peptide administration reduces colonic collagen deposition in mice with chronic TNBS colitis. (A)
Masson Trichrome staining for collagen in colonic tissues. Collagen was stained in blue with a red background. Collagen
deposited in the mucosal and submucosal layer of TNBS-treated mice was reduced by mCRAMP peptide treatment. (B)
Fibrosis score of colonic tissues. The elevated ﬁbrosis score of TNBS-treated mice (P ¼ .0001) was statistically signiﬁcantly
reduced by mCRAMP peptide treatment (P ¼ .0001). (C) Quantitative real-time RT-PCR of collagen col1a2 mRNA expression
in colonic tissues of mice. TNBS treatment statistically signiﬁcantly induced colonic col1a2 mRNA (P ¼ .0376) expression.
Intracolonic treatment of mCRAMP reduced colonic col1a2 mRNA expression (P ¼ .0364). Per group, n ¼ 6 mice.
58 Yoo et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 1previously described elsewhere.16 Cells (2  106 cells/
plate) were cultured in Dulbecco’s modiﬁed Eagle’s medium
containing 10% fetal bovine serum and 1% penicillin/
streptomycin and were serum starved overnight before
experiments. LL-37 peptide was purchased from
Biopeptide (San Diego, CA). TGF-b1, IGF-1, proinﬂammatory
cytokine cocktail (TNFa, IL-1b, and interferon-g,10 ng/mL each), U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-
aminophenylthio]butadiene) and PD98059 (2-(20-amino-30-
methoxyphenyl)-oxanaphthalen-4-one) were purchased
from Fisher Scientiﬁc (Pittsburgh, PA). LL-37, TGF-b1, IGF-1,
and the proinﬂammatory cytokine cocktail were dissolved
in triﬂuoroacetic acid (TFA) 0.1% as the vehicle solution.
PD98059 and U0126 were dissolved in dimethyl sulfoxide.
Figure 4. Cathelicidin reduces
collagen expression in colonic
ﬁbroblasts: immunoﬂuores-
cence staining of collagen
(red), ﬁbroblast marker
vimentin (green), and nuclei
DAPI (blue). In TNBS þ TFA,
intense red collagen staining
was observed in and around ﬁ-
broblasts that were identiﬁed by
green color. Overlapping images
of red collagen staining and
green vimentin staining resulted
in a yellowish color (lower right
corner), indicating colocalization
of collagen expression in ﬁbro-
blasts. The TNBS þ mCRAMP
treatment group and the ethanol
group had a low level of collagen
staining in and around the
vimentin green staining, indi-
cating low collagen expression
in ﬁbroblasts.
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60 Yoo et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 1Human primary intestinal ﬁbroblasts from normal subjects
and CD patients and cultured human colonic CCD-18Co ﬁ-
broblasts responded to TGF-b1 and/or IGF-1 differently.A
CBased on preliminary experiments, we used two different
conditions (TGF-b1 alone and TGF-b1 þ IGF-1) to stimulate
collagen expression. IGF-1 alone was not sufﬁcient to induceB
D
E
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shown).
Trinitrobenzene Sulphonic Acid Chronic
Colitis Model
Camp/ mice in C57BL/6J strain were obtained from
Dr. Richard Gallo at the University of California–San Diego
and were bred and maintained at the University of Cal-
ifornia–Los Angeles (UCLA) animal facility under standard
environmental conditions. The animal studies were
approved by the animal research committee of UCLA.
Chronic TNBS-associated colitis was induced as previously
reported elsewhere.14,15 Mice (8–9 weeks old) were injected
with TNBS solution or 30% ethanol (50 mL) intracolonically
for 5 weeks as illustrated in Figure 1 A. Intracolonic
administration was achieved by inserting a polyethylene
(PE10) catheter 3 cm into rectum under light isoﬂurane
anesthesia. A group of mice were injected with 5 mg/kg of
mCRAMP intracolonically every 3 days starting at week 5.
Another mouse group were injected with Camp-expressing
lentivirus (1  107 infectious units/mouse) or hemaggluti-
nin (HA)-expressing lentivirus intravenously once, starting
at week 5 as illustrated in Figure 6 A. Colonic tissues were
obtained at week 6 or 7 after carbon dioxide euthanasia.
Salmonella Infection Model
Wild-type mice in 129Sv/J strain were obtained from
Jackson Laboratory (Bar Harbor, ME) and were maintained at
the UCLA animal facility under standard environmental con-
ditions. Each mouse was administered 20mg of streptomycin
by oral gavage. The Salmonella typhimurium SL1344 strain
was obtained from Dr. Richard Issacson (University of Min-
nesota) and was cultured in Lysogeny broth (LB broth) for 48
hours. At 24 hours later, the mice were given Salmonella
typhimurium SL1344 strain 1 108 cfu or LB broth in 100 mL
by oral gavage as previously described elsewhere.13 Some
groups were injected with Camp-expressing lentivirus (1 
107 infectious units/mouse) or HA lentivirus intravenously
once starting on day 11, as illustrated in Figure 8A. Cecal tis-
sueswere obtainedonday21 after carbon dioxide euthanasia.
Virus Production and Transduction
The generation of cathelicidin-expressing lentivirus was
performed by UCLA vector core facility. Lentivirus-based
vectors encoding CRAMP were generated by transient
cotransfection of human embryonic kidney 293T (HEK293T)Figure 5. (See previous page). Intracolonic cathelicidin pept
cathelicidin-deﬁcient mice with chronic TNBS colitis. (A) Rep
based on H&E staining images of colonic tissues. TNBS treatmen
tistically signiﬁcantly higher histology score (P ¼ .001) compared
tically signiﬁcantly reduced the histology score in Camp/ mice
tissues. Collagen was stained in blue. Collagen deposited in muco
reducedbymCRAMPpeptide treatment. (D) Quantitative real-time
of mice. TNBS treatment statistically signiﬁcantly induced colonic
mCRAMP reduced colonic col1a2 mRNA expression in Camp/
inducedcolonicTnfaprotein (P¼ .0042 inwild-type;P¼ .0241 inC
statistically signiﬁcantly reduced TNBS-induced Tnfa protein expcells with a three-plasmid combination, as described previ-
ously elsewhere, with slight modiﬁcations.17 Brieﬂy, 8 
T175 ﬂasks of nonconﬂuent HEK293T cells were cotrans-
fectedwith 39mg pMDLg/pRRE, 21mg of pMDG (encoding the
VSV-G envelope), 15 mg of pRSV-REV, and 60 mg pRRL-CMV-
CRAMP-Ires green ﬂuorescent protein (GFP) by the CaPi-
DNA coprecipitation method.18,19 The plasmid vectors were
kindly provided by Dr. Luigi Naldini (University of Torino,
Italy). The next day, the mediumwas adjusted to make a ﬁnal
concentration of 10 mM sodium butyrate, and the cells were
incubated for 5 hours to obtain high-titer virus production as
previously described elsewhere.20 After the 5-hour incuba-
tion, the cells were washed and incubated in fresh medium
without sodium butyrate. Conditioned medium was har-
vested 16 hours later and passed through 0.45-mm ﬁlters.
The harvested supernatant was transferred into a centrifuge
tube and layered on top of a 10-mL 20% (w/v) sucrose
cushion. The tubes were centrifuged using a SW28 rotor
(Beckman Coulter, Brea, CA) for 2 hours at 22,000 rpm at 4C.
The virus-containing pellet was resuspended by gentle
agitation in an appropriate volume of Dulbecco’s phosphate-
buffered saline, followed by a short centrifugation step
(5 minutes at 16,000g) to pellet debris. Finally, the opaque
pelletwas transferred to a new tube. The biological titer of the
LVs carrying the enhanced green ﬂuorescent protein (eGFP)
reporter was analyzed by transduction of HEK293T cells
followed by ﬂow cytometry and infectious particles/mLwere
calculated as previously described elsewhere.21
Histologic Scoring
Murine colonic tissues were ﬁxed, sectioned, and stained
with H&E. Microphotographs at 200 magniﬁcation were
recorded at multiple locations and analyzed by two in-
vestigators in a blinded manner, scoring the specimens on a
0–12 scale for chronic TNBS colitis as previously described
elsewhere.22 The ﬁbrosis score for both TNBS and Salmo-
nella models was determined as previously described else-
where.23 In brief, several mucosal and submucosal locations
for each Masson trichrome–stained slide were evaluated on
a 0–3 scale (0 ¼ no ﬁbrosis, 1 ¼ mild ﬁbrosis, 2 ¼ moderate
ﬁbrosis, and 3 ¼ severe ﬁbrosis).
Mouse TNF-a, Mouse and Human TGF-b1
Enzyme-Linked Immunosorbent Assay
The levels of mouse TNF-a (DY410), mouse TGF-b1
(DY1679) and human TGF-b1 (DY240) of R&D Systemside administration reduces colonic collagen deposition in
resentative H&E images of colonic tissues. (B) Histology score
t in Camp/ mice led to increased tissue damage with a sta-
with the ethanol control. Peptide treatment of mCRAMP statis-
(P ¼ .04). (C) Masson Trichrome staining for collagen in colonic
sal and submucosal layer of TNBS treated Camp/mice was
RT-PCRof collagen col1a2mRNAexpression in colonic tissues
col1a2 mRNA (P¼ .0311) expression. Intracolonic treatment of
 (P ¼ .04) mice. (E) TNBS treatment statistically signiﬁcantly
amp/mice) expression. IntracolonicmCRAMPadministration
ression in Camp/ (P ¼ .0054) mice. Per group, n ¼ 6 mice.
62 Yoo et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 1(Minneapolis, MN) were measured by the enzyme-linked
immunosorbent assay kits according to manufacturer’s
instructions.A
CQuantitative Real-Time Reverse-Transcription
Polymerase Chain Reaction
Total RNA was isolated with the RNeasy kit (Qiagen,
Valencia, CA) and reversed transcribed into cDNA by aB
D
E
Figure 6. (See previous page). Lentiviral cathelicidin expression reduces colonic inﬂammation in TNBS-mediated chronic
colitis in mice. (A) Illustration of experimental plan of TNBS-mediated chronic colitis with LV vector protocol. Mice were injected
with increasing doses of TNBS solution intracolonically once a week for 6 weeks as described inMethods. Some mice received
intravenous injection ofmouse cathelicidinCamp-HA-expressing lentivirus orHA-expressing lentivirus (control), starting from the
ﬁfth TNBS injection. Colonic changes were evaluated 1 week after the last TNBS injection. (B) Colonic CampmRNA expression
was statistically signiﬁcantly increased in theCamp-LV group (P¼ .026 andP¼ .0413). (C) RepresentativeH&E images of colonic
tissues. (D) Histology score based on H&E staining images of colonic tissues. TNBS treatment in mice led to increased tissue
damagewith a statistically signiﬁcantly higher histology score (P¼ .001) comparedwith the ethanol control. Treatment ofCamp-
LV statistically signiﬁcantly reduced the histology score (P ¼ .0034). (E) Percentage of body weight change of different groups
(from week 0 to week 6). Cathelicidin-expressing LV infection did not alter mice body weight. Per group, n ¼ 6 mice.
A B
C
Figure 7. Lentiviral cathelicidin expression reduces colonic collagen deposition in mice with chronic TNBS colitis. (A)
Masson Trichrome staining for collagen in colonic tissues. Collagen deposited in the mucosal and submucosal layer of TNBS-
treated mice was reduced by Camp-expressing LV treatment. (B) Fibrosis score of colonic tissues. The elevated ﬁbrosis score
of TNBS-treated mice was statistically signiﬁcantly reduced by Camp-expressing lentivirus treatment (P ¼ .0001). (C) Colonic
col1a2 mRNA expression was statistically signiﬁcantly reduced in Camp-lentivirus group (P ¼ .0497). Per group, n ¼ 6 mice.
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64 Yoo et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 1Superscript III kit (no. 11752; Invitrogen). Quantitative
reverse-transcription polymerase chain reaction (RT-PCR)
reactions were run with an ABI Prism 7500 Fast sequenceA
Cdetector system (Applied Biosystems, Foster City, CA) as we
have previously described elsewhere.15 The levels of mRNA
were determined by using cataloged primers (Invitrogen) forB
D
E
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mousevimentin (Mm01333430_m1),18S (Hs99999901_s1)and
mouse Col1a2 (Mm01309565_m1), Camp (Mm00438285_m1),
Tgf-b1 (Mm01178820_m1), Tnfa (Mm00443259_g1), and
Gapdh (Mm99999915_g1). Results were expressed as relative
fold difference.Masson Trichrome Staining
Staining of collagen deposition of colonic tissue sections
was performed by Masson Trichrome staining kit (HT-10;
Sigma-Aldrich, St. Louis, MO) and Bouin solution (HT-
10132) as previously described elsewhere.15Immunoﬂuorescence Staining
Frozen mouse colonic tissues were embedded in opti-
mum cutting temperature solution and ﬁxed in acetone.
After incubation with blocking buffer, slides were incubated
with primary antibodies including rabbit polyclonal
anticollagen sc-28655, rabbit polyclonal anti-PCNA (anti-
proliferating cell nuclear antigen) sc-7907, or goat poly-
clonal antivimentin sc-7557 (1:50 dilution) for 2 hours at
room temperature, washed with phosphate-buffered saline
and incubated with ﬂuorescent-conjugated secondary anti-
bodies, including donkey anti-rabbit Texas Red sc-2784 and
bovine anti-goat FITC sc-2348, for 1 hour (1:100 dilution).
Slides were then rinsed and mounted with 4,6-diamidino-2-
phenylindole (DAPI) mounting solution. Images were
analyzed with a AX10 confocal microscope (Carl Zeiss,
Thornwood, NY).Immunohistochemistry
Colon tissues were ﬁxed in 4% paraformaldehyde and
embedded in parafﬁn. After incubation with blocking buffer,
the sections were incubated with a goat polyclonal anti-
vimentin antibody (sc-7557, 1:50 dilution; Santa Cruz
Biotechnology, Santa Cruz, CA), a rabbit polyclonal anti-F4/
80 antibody (sc-26643-R, 1:50 dilution; Santa Cruz
Biotechnology), or a rabbit polyclonal anti-phospho-ERK
antibody (no. 4370, 1:50 dilution; Cell Signaling Technolo-
gies, Danvers, MA) overnight at 4C. After washing, the
sections were incubated with donkey anti-goat IgG or
bovine anti-rabbit IgG, and the slides were stained with an
ABC kit for color development (sc-2018; Santa Cruz
Biotechnology). Immunohistochemistry was assisted by
Translational Pathology Core Laboratory (TPCL) of UCLA.Figure 8. (See previous page). Lentiviral cathelicidin express
cecal inﬂammation in mice. (A) Illustration of the experimental p
protocol. Mice were fed with streptomycin to reduce the microﬂ
later, the mice were inoculated with Salmonella. Some mice rec
expressing lentivirus or control lentivirus on day 11. Cecal c
expression was statistically signiﬁcantly increased in the Salmon
LV group (P ¼ .0001 and P ¼ .0317). (C) Representative H&E ima
staining images of colonic tissues. TNBS treatment in mice led
higher histology score (P ¼ .0001) compared with the ethanol co
histology score (P ¼ .0001). (E) Salmonella infection statistically s
Camp-lentivirus treatment signiﬁcantly reduced Salmonella induImages were analyzed with a Zeiss AX10 microscope at
magniﬁcation of 200.
Western Blot Analyses
Cells were lysed in radioimmunoprecipitation assay
buffer with proteinase inhibitor cocktail (Cell Signaling
Technologies). Equal amounts of cell extracts were fraction-
ated by 10% sodium dodecyl sulfate polyacrylamide gel
electrophoresis, and proteins were transferred onto nitro-
cellulose membranes (400 mA for 1.5 hours at 4C; Bio-Rad
Laboratories, Hercules, CA). Membranes were blocked in
5% nonfat milk in TBST (50 mM Tris, pH 7.5, 0.15M NaCl,
0.05% Tween 20), and then were incubated with antibodies
against phospho-extracellular signal-regulated kinase
(phospho-ERK) (no. 4370), b-tubulin (no. 2146; Cell
Signaling Technologies), phospho-epidermal growth factor
receptor (phospho-EGFR) (no. sc12351; Santa Cruz
Biotechnology), pro-COL1A1 (no. SP1D8; Development
Studies Hybridoma Bank, Iowa City, IA). Horseradish
peroxidase-labeled antibodies were detected by chem-
iluminescence (Fisher Scientiﬁc, Pittsburgh, PA), and the
signals were captured using the luminescent image analyzer
LAS4000 (Fujiﬁlm, Tokyo, Japan).
Statistical Analyses
Results were expressed as mean ± standard error of the
mean (SEM) and were analyzed by using the Prism pro-
fessional statistics software program (GraphPad, San Diego,
CA). Unpaired Student t tests were used for intergroup
comparisons. P values of statistically signiﬁcant differences
are shown in each ﬁgure.
Results
Cathelicidin Reduces Chronic, TNBS-Induced
Colitis in Mice
We have previously shown that cathelicidins have anti-
inﬂammatory effects against DSS-induced colitis and C
difﬁcile infection in mice.11,12 To investigate the role of
cathelicidin in chronic colitis, mice were administered a low
dose of TNBS intracolonically every week as previously
described elsewhere.14,15 The experimental design of these
experiments is illustrated in Figure 1A. After 7 weeks, the
body weight of the TNBS-treated mice was statistically
signiﬁcantly lower (P ¼ .045) compared with that of
ethanol-treated (control) mice (Figure 1B). Intracolonic
administration of the mCRAMP peptide to TNBS-exposedion reduces colonic inﬂammation in Salmonella-induced
lan of Salmonella-mediated cecal inﬂammation with LV vector
ora load in the intestine and facilitate infection, and 24 hours
eived intravenous injection of mouse cathelicidin Camp-HA-
hanges were evaluated on day 21. (B) Cecal Camp mRNA
ella-infected group and was further augmented in the Camp-
ges of colonic tissues. (D) Histology score was based on H&E
to increased tissue damage with a statistically signiﬁcantly
ntrol. Treatment of Camp-LV statistically signiﬁcantly reduced
igniﬁcantly induced cecal TnfamRNA (P ¼ .0001) expression.
ced Tnfa mRNA (P ¼ .0107) expression. Per group, n ¼ 6.
66 Yoo et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 1mice restored their body weight loss to levels similar to
those of the control mice (P ¼ .0178, Figure 1B). Moreover,
chronic TNBS administration induced colonic tissue damage
with statistically signiﬁcantly higher (P ¼ .001) histologicA B
C
Dscores compared with the damage induced in control mice
(Figure 1C and D). Intracolonic mCRAMP administration
statistically signiﬁcantly reduced the colonic histology score
(P ¼ .03) in TNBS-treated mice (Figures 1D).E
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colonic proinﬂammatory cytokine tumor necrosis factor a
(Tnfa) mRNA levels (P ¼ .0344; Figure 1E), which were
statistically signiﬁcantly reduced by mCRAMP administra-
tion (P ¼ .046, Figure 1E). Intracolonic TNBS also increased
colonic Tgf-b1 mRNA expression; intracolonic administra-
tion of cathelicidin did not alter this response (Figure 1F).
However, intracolonic mCRAMP did not change the
increased colonic F4/80-positive macrophage inﬁltration in
TNBS-treated mice (Figure 2). Thus, intracolonic adminis-
tration of cathelicidin reduced chronic experimental colitis
in an IBD mouse model, consistent with our results in the C
difﬁcile infection model of colitis.12Cathelicidin Reduces Chronic Colitis-Associated
Collagen Expression
Intestinal ﬁbrosis with stricture formation is an impor-
tant complication in CD patients.3 We next evaluated the
effect of intracolonic cathelicidin in TNBS colitis-associated
colonic ﬁbrosis with Masson trichrome staining for
collagen formation. We found increased collagen deposition
in the colon of TNBS-treated mice, both in the mucosa and
submucosa, compared with control mice (Figure 3A), which
was in line with previous observations.14,15 Increased
ﬁbrosis was also reﬂected by an increased ﬁbrosis score
(Figure 3B). Moreover, compared with ethanol treatment,
chronic TNBS administration increased the collagen Col1a2
mRNA colonic expression (P ¼ .0376, Figure 3C) that was
statistically signiﬁcantly reduced by intracolonic mCRAMP
administration (P ¼ .0364, Figure 3C), suggesting anti-
ﬁbrogenic effects. Double immunoﬂuorescence staining
showed increased colonic collagen protein expression in
and around vimentin-expressing ﬁbroblasts in TNBS-treated
mice (Figure 4). Colocalization of collagen and vimentin
indicates that ﬁbroblasts are main sources of collagen
expression. Intracolonic mCRAMP peptide administration
also reduced collagen expression in and around colonic ﬁ-
broblasts of TNBS-treated mice (Figure 4).
On the other hand, cathelicidin-deﬁcient mice showed
similar colonic histologic damage (Figure 5A and B), collagen
expression (Figure 5C and D), or TNFa protein levels
(Figure 5E) as the wild-type mice in chronic TNBS colitis. Our
data also indicate that expression of endogenous colonic
cathelicidin in wild-type mice was not induced during
chronic TNBS colitis (Figure 6B). However, intracolonic
cathelicidin mCRAMP administration reduced colonic tissue
damage (Figure 5A and B) and exerted antiﬁbrogenic effects
in TNBS-treated Camp/ mice (Figure 5C and D).Figure 9. (See previous page). Lentiviral cathelicidin expre
Salmonella-induced cecal ﬁbrosis. (A) Percentage of body w
monella- or cathelicidin-expressing LV infection did not alter t
collagen in colonic tissues. Collagen deposited in mucosal and
by Camp-expressing lentivirus treatment. (C) Fibrosis score o
infected mice was statistically signiﬁcantly reduced by Camp-ex
expression was statistically signiﬁcantly reduced in the Camp-le
in mice with Salmonella infection. Salmonella infection increas
increase was not affected by Camp-lentivirus. Per group, n ¼ 6Lentiviral Expression of Cathelicidin Reduces
Colitis-Associated Intestinal Fibrosis
To further examine the effects of cathelicidin in colitis-
associated ﬁbrosis, we injected intravenously cathelicidin-
overexpressing lentiviruses and determined their effects in
the chronic TNBS-associated model of colitis and colonic
ﬁbrosis using the experimental approach shown in
Figure 6A. We found that intravenous administration of
cathelicidin-expressing lentiviruses increased colonic cath-
elicidin mRNA levels compared with the injection of control
lentiviruses (Figure 6B). Moreover, injection of cathelicidin-
overexpressing lentiviruses signiﬁcantly reduced the histo-
logic damage and histology scores in response to chronic
TNBS administration (Figure 6C and D) without affecting the
body weight changes in response to TNBS (Figure 6E).
Lentiviral overexpression of cathelicidin also inhibited
TNBS-induced collagen deposition in the colon, as reﬂected
by a statistically signiﬁcant reduction in the colonic ﬁbrosis
score (P ¼ .0001, Figure 7A and B) and reduced colonic
collagen Col1a2 mRNA expression (P ¼ .0497, Figure 7C).
Lentiviral Expression of Cathelicidin Reduces
Cecal Fibrosis during Salmonella Infection
Salmonella induces intestinal inﬂammation and ﬁbrosis
in a TH1 and TH17-dependent manner.
13 Thus, we next
examined whether injection of LV-overexpressing cath-
elicidin has any effect on Salmonella-induced ﬁbrosis using
the experimental design shown in Figure 8A. Interestingly,
Salmonella infection by itself resulted in increased mRNA
levels of cecal cathelicidin (P ¼ .0001; Figure 8B), which
was further increased by injection of cathelicidin-expressing
lentiviruses in the inﬂamed cecum (P ¼ .0317, Figure 8B).
As shown by H&E staining, Salmonella caused severe cecal
inﬂammation and tissue damage that was reduced by len-
tiviral cathelicidin expression (Figure 8C and D). Cath-
elicidin overexpressing lentiviruses also statistically
signiﬁcantly reduced Salmonella-induced proinﬂammatory
cytokine TnfamRNA expression (P ¼ .0107) (Figure 8E). No
change in body weight was observed in any of the
Salmonella-infected groups (Figure 9A).
Masson trichrome staining indicated strong cecal collagen
deposition in Salmonella-infected mice, which was dimin-
ished by LV cathelicidin overexpression (Figure 9B), reﬂected
by a statistically signiﬁcant reduction in the ﬁbrosis score
(P ¼ .0001, Figure 9C) and cecal collagen mRNA expression
(P ¼ .0251, Figure 9D). Overexpression of cathelicidin in
Salmonella-infected mice did not statistically signiﬁcantly
affect cecal Tgf-b1 mRNA expression (Figure 9E).ssion reduces colonic collagen deposition in mice with
eight change of different groups (from day 0 to day 21). Sal-
he body weight of mice. (B) Masson Trichrome staining for
submucosal layers of Salmonella-infected mice was reduced
f colonic tissues. The elevated ﬁbrosis score of Salmonella-
pressing LV treatment (P ¼ .0001). (D) Colonic col1a2 mRNA
ntivirus group (P ¼ .0251). (E) Cecal Tgf-b1 mRNA expression
ed the cecal Tgf-b1 mRNA expression (P ¼ .0091), but the
mice.
A B
C
D E
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Figure 11. Cathelicidin reduces collagen expression in human CCD-18Co colonic ﬁbroblasts. (A and B) Human colonic
CCD-18Co ﬁbroblasts were incubated with TGF-b1 (50 ng/mL) and IGF-1 (10 ng/mL) or TGF-b1 (5 ng/mL) alone with or without
LL-37 for 8 hours. Western blot analyses showed that TGF-b1 and IGF-1 together (P ¼ .0001) and TGF-b1 (P ¼ .0001) alone
induced pro-COL1A1 protein expression. LL-37 (5 mM) statistically signiﬁcantly suppressed collagen expression in the
presence of TGF-b1 and IGF-1 together (P ¼ .0001) or TGF-b1 alone (P ¼ .0001). Results are representative of three inde-
pendent experiments.
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Induced by TGF-b1 and IGF-1 in Human
Intestinal Fibroblasts
In the mucosa of CD strictures, TGF-b1 and IGF-1 stim-
ulate collagen expression in intestinal ﬁbroblasts, leading to
ﬁbrosis.3 Previous studies indicated that TGF-b1 stimulates
collagen synthesis in lung and dermal ﬁbroblasts.24 To
study the antiﬁbrogenic mechanism of cathelicidin, we
coincubated human primary normal intestinal ﬁbroblasts
with TGF-b1 (5 ng/mL) together with human cathelicidin
(LL-37, 5 mM). TGF-b1 alone stimulated procollagen 1A1
protein expression (P ¼ .0001) in human primary normal
intestinal ﬁbroblasts after 48 hours (Figure 10A and B).
Coincubation with human cathelicidin statistically signiﬁ-
cantly reduced TGF-b1-stimulated (P ¼ .0001) procollagen
1A1 protein expression (Figure 10A and B). Similarly, LL-37
statistically signiﬁcantly inhibited TGF-b1-stimulated
COL1A2 mRNA expression in human primary intestinal ﬁ-
broblasts (Figure 10C) and also reduced procollagen 1A1
protein expression induced by TGF-b1 in human primary
intestinal ﬁbroblasts isolated from CD patients (Figure 10D
and E). Moreover, in cultured human colonic CCD-18CoFigure 10. (See previous page). Cathelicidin reduces collagen
B) Human primary intestinal ﬁbroblasts isolated from normal sub
mL) or TGF-b1 (5 ng/mL) alone with or without LL-37 for 48 ho
alone induced pro-COL1A1 protein expression. LL-37 (5 mM) st
presence of TGF-b1 alone (P ¼ .0001). (C) Serum-starved huma
LL-37 (5 mM), and/or TGF-b1 (5 ng/mL) for 16 hours. LL-37 s
induced by TGF-b1. (D and E) Human primary intestinal ﬁbroblas
IGF-1 (10 ng/mL) together or TGF-b1 (5 ng/mL) alone with or
showed that both TGF-b1 (50 ng/mL) and IGF-1 (10 ng/mL) toge
expression. LL-37 (3 mM) statistically signiﬁcantly suppressed
(P ¼ .0001). The results are representative of three healthy indiﬁbroblasts, cathelicidin inhibited TGF-b1- and/or IGF-1-
induced collagen protein synthesis (Figure 11).Cathelicidin Reduces Collagen Expression in
Human Colonic Fibroblasts via ERK Activation
ERK activation has been shown to be involved in the
antiﬁbrogenic effects of cathelicidin in dermal ﬁbroblasts.9
We hypothesized that ERK may represent a pathway
modulating the antiﬁbrogenic effects of cathelicidin in pri-
mary intestinal ﬁbroblasts. We found that LL-37-induced
inhibition of TGF-b1-mediated collagen protein expression
in human primary normal intestinal ﬁbroblasts was
partially reversed by pretreatment of cells with the
ERK inhibitors PD98059 and U0126 (Figure 12A). More-
over, cathelicidin induced ERK phosphorylation in a
concentration-dependent manner regardless of the presence
of TGF-b1 or IGF-1 in human normal primary intestinal ﬁ-
broblasts (Figure 12B). Consistent with these ﬁnding,
cathelicidin-induced ERK phosphorylation (addition of EGF
serving as a positive control), but not EGFR phosphorylation
in human CCD-18Co colonic ﬁbroblasts (Figure 13A).expression in human primary intestinal ﬁbroblasts. (A and
jects were treated with TGF-b1 (50 ng/mL) and IGF-1 (10 ng/
urs. Western blot analyses showed that TGF-b1 (P ¼ .0001)
atistically signiﬁcantly suppressed collagen expression in the
n primary normal intestinal ﬁbroblasts were exposed to TFA,
tatistically signiﬁcantly inhibited collagen mRNA expression
ts from a CD patient were treated with TGF-b1 (50 ng/mL) and
without LL-37 (0–3 mM) for 48 hours. Western blot analyses
ther and TGF-b1 (5 ng/mL) alone induced pro-COL1A1 protein
collagen expression in the presence of TGF-b1 and/or IGF-1
viduals and two CD patients.
A B
Figure 12. Antiﬁbrogenic effect of cathelicidin is ERK dependent. (A) Human primary normal intestinal ﬁbroblasts were
pretreated with dimethyl sulfoxide, MEK1 inhibitor PD98059 (10 mM), or MEK1/2 inhibitor U0126 (10 mM) for 30 minutes,
followed by LL-37 (5 mM) or TFA 0.1% and/or TGF-b1 (5 ng/mL) exposure for 48 hours. Pro-COL1A1 and GAPDH protein
expression was detected by Western blot. Blockade of ERK partially reversed the antiﬁbrogenic effects of cathelicidin. (B)
Human primary normal intestinal ﬁbroblasts were exposed to LL-37 (1–10 mM) or TFA 0.1% and/or TGF-b1 (50 ng/mL) and
IGF-1 (10 ng/mL) together or TGF-b1 (5 ng/mL) alone for 30 minutes. Cathelicidin activated ERK phosphorylation in human
ﬁbroblasts.
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cathelicidin in both human primary intestinal ﬁbroblasts
obtained from CD patients and human CCD-18Co colonic
ﬁbroblasts (Figure 13B–E). These results suggest that
cathelicidin inhibits ﬁbrogenesis via an ERK-dependent
pathway in native human colonic ﬁbroblasts.
To conﬁrm cathelicidin mediated ERK activation
in vivo, we determined ERK phosphorylation in submu-
cosal tissues of colons and cecum where most ﬁbroblasts
are populated. We found the submucosal tissues of
normal, TNBS-treated, or Salmonella-infected mice had a
low expression of phosphorylated ERK (Figure 14A and B).
Both intracolonic mCRAMP peptide administration and
intravenous Camp-expressing lentivirus administration
activated colonic or cecal ERK phosphorylation in
the TNBS or Salmonella model of intestinal ﬁbrosis
(Figure 14A and B).Discussion
We and others have previously shown that the
antimicrobial peptide cathelicidin possesses potent anti-
inﬂammatory activities against acute intestinal inﬂamma-
tion.10–12 Consistent with these ﬁndings, our results using the
models of chronic TNBS colitis and Salmonella infection and
two different approaches—intracolonic administration of
cathelicidin peptide and intravenous injection of cathelicidin-
expressing lentiviruses—demonstrate that cathelicidin
exerts signiﬁcant anti-inﬂammatory effects, including
reduction of mucosal Tnfa protein or mRNA expression
(Figures 1E, 5E, and 8E). Both approaches also lead to sub-
stantial improvement of histologic evidence of colitis in both
animal models (Figures 1D, 5B, 6D, and 8D). Taken togetherwith previous ﬁndings,10–12 our results demonstrate a role
for exogenous administration of cathelicidin against both
acute and chronic IBD-related colitis as well as infectious
colitis of different etiologies. Most importantly, we report
here that cathelicidin inhibits colitis-associated colonic
ﬁbrosis in chronic TNBS and Salmonella infection models
in vivo and in human intestinal ﬁbroblasts in vitro, suggesting
that exogenous cathelicidin may represent an effective
approach in inhibiting colitis-associated ﬁbrosis.
The role of antimicrobial peptides or proteins, including
cathelicidins, in colitis-associated intestinal ﬁbrosis or
stricture formation has never been reported. We report here
that cathelicidin inhibits colitis-associated colonic ﬁbrosis
in vivo and substantially reduces TGF-b1- and/or IGF-1-
mediated collagen protein synthesis in human intestinal ﬁ-
broblasts isolated from three normal subjects and two CD
patients (Figure 10A–E) as well as in human colonic CCD-
18Co ﬁbroblasts (Figure 11).
In rats, systemic blockade of putative cathelicidin
receptor P2X7 by A740003 [N-(1-([(cyanoimino)(5-
quinolinylamino) methyl] amino)-2,2-dimethylpropyl)-2-
(3,4-dimethoxyphenyl)acetamide] and brilliant blue G
preventedTNBS-induced colitis25while A438079 [3-[[5-(2,3-
dichlorophenyl)-1H-tetrazol-1-yl]methyl]pyridine], another
P2X7 inhibitor, reduced mouse liver ﬁbrosis.26 Another pu-
tative cathelicidin receptor formyl peptide receptor-like 1
(FPRL1) was found to mediate LL-37-induced collagen pro-
duction in human lung ﬁbroblasts.27 However, the anti-
ﬁbrogenic effect of LL-37 in human intestinal ﬁbroblasts was
not altered by pretreatment with the FPRL1 antagonist
WRW4 or the P2X7 antagonist KN62 (data not shown), sug-
gesting that the antiﬁbrogenic effects of cathelicidin do not
depend on these two putative cathelicidin receptors.
AB C
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Figure 13. Epidermal growth factor–mediated MAP kinase activation promotes the antiﬁbrogenic effects of cath-
elicidin. (A) Serum-starved CCD-18Co ﬁbroblasts were exposed to 5 mM of LL-37 (0–30 minutes) or EGF (500 ng/mL, 30
minutes). Protein lysate was used for Western blot analyses. LL-37 induced the phosphorylation of ERK but not EGFR. EGF (as
a positive control) induced both ERK and EGFR phosphorylation. (B) Serum-starved human primary intestinal ﬁbroblasts were
exposed to TFA, LL-37 (1–3 mM), or EGF (500 ng/mL) for 48 hours. Collagen protein expression was determined by Western
blot analysis. (C) Quantitative analysis of the Western blot. EGF statistically signiﬁcantly promoted cathelicidin-mediated in-
hibition of collagen expression in ﬁbroblasts (LL-37 1 mM, P ¼ .0001; LL-37 3 mM, P ¼ .0001). (D) Serum-starved CCD-18Co
colonic ﬁbroblasts were exposed to TFA, LL-37 (3–5 mM), or EGF (500 ng/mL) for 8 hours. Collagen protein expression was
determined by Western blot analysis. (E) Quantitative analysis of the Western blot. EGF statistically signiﬁcantly promoted
cathelicidin-mediated inhibition of collagen expression in ﬁbroblasts (LL-37 3 mM, P ¼ .0001; LL-37 5 mM, P ¼ .0001). The
results are representative of two independent experiments.
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Figure 14. Cathelicidin activates ERK phosphorylation in submucosal tissue in vivo. (A) Immunohistochemistry of
phospho-ERK in mouse colons. Both normal control and TNBS-treated groups had low phospho-ERK signal in submucosal
tissue. TNBS-treated mice with intracolonic mCRAMP peptide administration or intravenous Camp-expressing lentivirus
administration had more phospho-ERK signal. (B) Immunohistochemistry of phospho-ERK in mouse cecum. Both normal
control and Salmonella-treated groups had a low phospho-ERK signal in submucosal tissue. Salmonella-treated mice with
intravenous Camp-expressing LV administration had more phospho-ERK signal. Per group, n ¼ 6 mice.
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Figure 15. Cathelicidin
does not affect TGF-b1
expression in ﬁbroblasts.
(A) CCD-18Co ﬁbroblasts
were treated with proin-
ﬂammatory cytokine cock-
tail with orwithout LL-37 for
48 hours. TGF-b1 protein
secretion from CCD-18Co
was not affected by cath-
elicidin. (B) TGF-b1 protein
remaining in the cell lysate
was not affected by cath-
elicidin. The results are
representative of three in-
dependent experiments.
January 2015 Antiﬁbrogenic Effects of Cathelicidin in Chronic Colitis 73This antiﬁbrogenic effect likely involves an ERK-
dependent mechanism as it can be blocked by the mitogen-
activated protein kinase 1 (MEK1) inhibitor PD98059 and
the MEK1/2 inhibitor U0126 (Figure 12A). Cathelicidin in-
duces ERK phosphorylation in human normal intestinal ﬁ-
broblasts and human CCD-18Co colonic ﬁbroblasts
(Figures 12B and 13A). Speciﬁcally, the effects of cathelicidin
in collagen synthesis appear to be mediated by MEK1, as the
MEK1 inhibitor PD98059 was sufﬁcient to reverse LL-37-
mediated suppression of TGF-b1-induced collagen synthe-
sis (Figure 12A). These results conﬁrm that the antiﬁbrogenic
effects of cathelicidin in intestinal ﬁbroblasts are ERK-
dependent and are consistent with a previous report
demonstrating that the antiﬁbrogenic mechanism of cath-
elicidin in dermal ﬁbroblasts involves ERK activation.9
Cathelicidin did not affect protein expression of the
ﬁbrogenic TGF-b1 in CCD-18Co colonic ﬁbroblasts, even in
the presence of a proinﬂammatory cytokine cocktail (TNFa,
IL-1b, and interferon-g) (Figure 15A and B). Moreover,
intracolonic cathelicidin administration or injection of
cathelicidin-overexpressing lentiviruses did not affect in-
testinal TGF-b1 mRNA expression in both TNBS and Sal-
monella ﬁbrosis mouse models (Figures 1F and 9E). These
results suggest that the antiﬁbrogenic effects of cathelicidin
are independent of the classic TGF-b1-mediated proﬁbro-
genic events.
On the other hand, cathelicidin treatment did not induce
ﬁbroblast cell proliferation in vitro, and did not affect
colonic or cecal expression of the ﬁbroblast marker
vimentin expression (data not shown) and proliferating cell
nuclear antigen staining (Supplementary Figure 1) in our
in vivo models. We did not observe colonic apoptosis (ter-
minal deoxynucleotidyl transferase–mediated deoxyuridine
triphosphate nick-end labeling assay) after intracolonic or
intravenous cathelicidin administration (data not shown),
suggesting that cathelicidin is unlikely to cause tissue
damage in the intestine.Despite the positive antiﬁbrogenic effects of cathelicidin
administration, TNBS-treated cathelicidin-deﬁcient mice did
not show additional colonic ﬁbrosis or tissue damage
compared with TNBS-treated wild-type mice (Figure 5). The
lack of increased endogenous cathelicidin expression
(Figure 6B) may be related to low levels of inﬂammation seen
in this chronic TNBS-inducedmodel as reﬂectedby lowcolonic
TNFa protein level (Figure 5E). Colonic TNFa levels were
similar among TNBS treated wild-type and Camp/ mice
(Figure 5E). Although colonic cathelicidin mRNA expression is
increased in acute DSS-induced colitis,11 intestinal cathelicidin
mRNA expression is not altered in CD patients.28
Several studies have underlined the importance of the
bacterial composition of the intestinal ﬂora in IBD patho-
physiology and epithelial barrier integrity. Along these lines,
the ability of cathelicidin to alter the gut microﬂora may be
associated with the antiﬁbrogenic effects reported here.10,11
Because the microﬂora composition associated with intesti-
nal ﬁbrosis has not been identiﬁed in animal or human colon,
future studies are necessary to explore this possibility.
In summary, our report provides novel evidence for an
antiﬁbrogenic effect of cathelicidin in vivo and in vitro. Our
results strongly suggest that cathelicidin administration
may be a novel approach to prevent or treat IBD, and IBD-
related colonic ﬁbrosis.
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Supplementary Figure 1. Cathelicidin did not affect cell proliferation in colonic tissues. Immunoﬂuorescence staining of cell
proliferation marker PCNA (red), ﬁbroblast marker vimentin (green) and nuclei DAPI (blue). In TNBSþTFA, weak red PCNA
staining was observed in and around ﬁbroblasts that were identiﬁed by green color. Overlapping images of red PCNA staining,
green vimentin staining and blue nuclear staining are shown in lower right corner. All groups had low level of PCNA staining in and
around vimentin green staining, indicating low cell proliferation in colonic ﬁbroblasts.
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